Research programme: monoclonal antibodies - Jinghua Pharmaceutical/Kadmon Corporation

Drug Profile

Research programme: monoclonal antibodies - Jinghua Pharmaceutical/Kadmon Corporation

Alternative Names: Anti-VEGFR2 and anti-PD-L1 monoclonal antibodies - Jinghua/Kadmon; KD-035; KD-036

Latest Information Update: 02 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kadmon Corporation
  • Developer Jinghua Pharmaceutical; Kadmon Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 20 Nov 2015 Fully human anti-VEGFR 2 and anti-PD L1 monoclonal antibodies licensed to Jinghua Pharmaceutical in China
  • 20 Nov 2015 Jinghua Pharmaceutical in-licenses technology to discover technology fully human monoclonal antibodies from Kadmon Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top